![\"Doctor](\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/06\/847ea0b9bc8d0797fd9ac60d9b2ac773.jpeg\")
Image source: Getty Images. Medtronic reports best growth in a decade <\/p>\n
Last week, Medtronic posted its year-end numbers for fiscal 2026 (which ended April 24). The results were impressive, with the healthcare company<\/a> boasting of the highest growth rate it achieved in 10 years. While sales didn’t double or triple, they rose by 8.4% for the full year. That’s high for a business that in recent years has struggled to grow its top line. Management credits the results to “disciplined execution across our portfolio and continued operational rigor.” Meanwhile, it still expects to generate more growth in the long run, particularly as it makes more investments in its pipeline.<\/p>\n The company’s products and therapies help treat 70 different health conditions. And with a presence in over 150 countries, this is a vast and diversified business to invest in, giving you exposure to opportunities in healthcare that expand beyond just the U.S. market.<\/p>\n A low valuation and high yield sweeten the deal for investors <\/p>\n Single-digit growth may not be enough to convince you of a reason to invest in Medtronic, but what could tip the scales is what else you get with the stock. The most enticing may be the high yield<\/a>, because at 3.5%, Medtronic offers a payout that’s more than three times what you’d get with the average S&P 500 stock that pays just 1%. The dividend has also been growing, and with the recent increase, Medtronic’s streak extends to 49 years, making it highly probable that the recurring income you receive from the stock will rise higher in the future.<\/p>\n Another appealing reason to own the stock is for its low valuation; currently, Medtronic’s stock is trading at a forward price-to-earnings multiple of 14, based on analyst estimates of its future earnings. That’s a modest price tag for a solid business that’s profitable and growing at a decent pace.<\/p>\n Between the yield, the dividend income, and the strong results, Medtronic may be one of the best bargains in the market right now. Although the stock is down 15% this year, as a long-term investment, it may be a no-brainer buy.<\/p>\n Should you buy stock in Medtronic right now? <\/p>\n Before you buy stock in Medtronic, consider this:<\/p>\n The Motley Fool Stock Advisor analyst team just identified what they believe are the\u00a010 best stocks<\/a> for investors to buy now\u2026 and Medtronic wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.<\/p>\n Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation,\u00a0you\u2019d have $443,191!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you\u2019d have $1,258,838!*<\/p>\n Now, it\u2019s worth noting\u00a0Stock Advisor\u2019s total average return is 941% \u2014 a market-crushing outperformance compared to 206% for the S&P 500.\u00a0Don’t miss the latest top 10 list, available with\u00a0Stock Advisor, and join an investing community built by individual investors for individual investors.<\/p>\n See the 10 stocks \u00bb<\/a><\/p>\n *Stock Advisor returns as of June 8, 2026. <\/p>\n David Jagielski, CPA<\/a> has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Medtronic. The Motley Fool has a disclosure policy<\/a>.<\/p>\n